Key facts
- It has raised $100K; the latest was Early Stage VC ($100K) in Jan 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Eletala Enterprises
- ·The full record, as it builds
Funding rounds
No funding rounds for Eletala Enterprises are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eletala Enterprises
Developer of therapeutics designed to address physiological abnormalities and cerebral folate deficiency in ASD. The company offers a metabolic approach that helps to restore folate levels in the brain, enabling clients to improve receptive and expressive language by targeting underlying physiological abnormalities rather than just symptoms.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2025
- Website
- eletala.com/
- Ownership
- Privately Held (backing)
Eletala Enterprises doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eletala Enterprises shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eletala Enterprises in its N-PORT filings yet. We sweep new filings monthly.